Future pharmaceutical manufacturing overviews are turning to digitized data collection and integrated solutions to comply with regulations, improve visibility into the future of pharmaceutical manufacturing operations, and create a more transparent supply chain.
According to a new PMMI Business Intelligence report, “Pharmaceutical Manufacturing, Trends Shaping The Future,” nearly half of the pharma manufacturers interviewed are now collecting at least some data digitally, with a handful of operations at leading manufacturers collecting 100 percent of their data digitally. Of course, this also implies that half of the pharma companies polled are not collecting digital data, proving the adage that change is slow in the pharmaceutical industry.
The Medicines Manufacturing Innovation Centre, which CPI is establishing in Renfrewshire in collaboration with the University of Strathclyde, GSK, AstraZeneca, UKRI, and Scottish Enterprise, is taking a collaborative approach to solving pharmaceutical challenges and easing the strain on the healthcare system. Next-generation manufacturing processes in development can help to eliminate inefficiencies in the pharmaceutical supply chain, allowing drugs to reach the market in less time and at a lower cost. Furthermore, this innovative manufacturing facility will help position the UK as a global leader in the delivery of new, effective, and personalized medicines.
Change is on its way
The traditional model of healthcare is one in which patients become ill and present symptoms before going to the doctor, where they are then treated with first-line, best-in-class medication. Patients receive treatment and return to the doctor if they continue to feel ill, which may result in the administration of second-line medication. With the introduction of the Pap smear screening program into the UK health system, doctors were suddenly able to detect and treat cervical cancer before symptoms appeared. More recently, a better understanding of cell and molecular biology, as well as a significant decrease in the cost of genetic sequencing, has allowed biomarkers to become more prevalent in healthcare. Doctors can personalize treatment by knowing a patient’s unique biomarkers.
Providing cutting-edge manufacturing
CPI is a member of a unique collaboration working to establish the Medicines Manufacturing Innovation Centre in Renfrewshire, near Glasgow. The center will offer companies of all sizes a technologically advanced, GMP-compliant environment in which to develop a more agile, responsive medicines supply chain for the pharmaceutical industry through improved manufacturing processes. Finally, this will provide solutions to current supply chain inefficiencies, allowing new drugs to be brought to market faster and at a lower cost. To accomplish this, the center has established a series of Grand Challenges, each of which focuses on a specific problem raised by the industry. The new technology being developed to address these challenges will propel the United Kingdom to the forefront of pharmaceutical manufacturing.
Personal, modern, and innovative healthcare
To maintain the UK’s position as a healthcare leader and ensure that the NHS can continue to provide exceptional care to patients, innovative biologists, chemists, and engineers must collaborate to develop a better future for pharmaceutical manufacturing processes. The Medicines Manufacturing Innovation Centre is bringing together academic and industry experts to develop technology to address these challenges. This technology will allow pharmaceutical companies to quickly optimize drug manufacturing and produce them where and when they are needed. This not only reduces the cost of new medicines, but also strengthens the UK’s ability to deliver the healthcare system of the future – one that is agile, responsive, and personalized.
Cybersecurity is a major concern
Cybersecurity is a major concern for all manufacturers, including pharmaceutical companies. According to a recent survey, 70% of pharmaceutical companies consider cybersecurity to be one of their top operational concerns. This is a critical issue for pharmaceutical companies, which have vast amounts of proprietary patient data, some of which are collected remotely.
In conclusion, the future appears promising. Pharma companies have risen to the top of the therapy and disease treatment industries. the future of pharmaceutical manufacturing sciences capabilities, new technologies, R&D, new concepts, and manufacturing process optimization have all made significant contributions to drug development and effective treatments around the world.
Pharmaceutical Manufacturing markets are expected to grow rapidly. Favorable government policies, the introduction of new and advanced drugs, robust investment in the biotech/pharma sector, and rising demand for synthetic biology are driving the market. Nanotechnology will become more prevalent in the R&D sector. Agile concepts will transform not only R&D but also biotech/pharma manufacturing companies, assisting them in transforming their functions in a variety of applications.